New risk score links stress response to heart disease, enhancing prediction and prevention in coronary artery disease ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

BACKGROUND: The optimal coronary stenting technique for true left main bifurcation lesions is uncertain. EBC MAIN (European ...

The statistics from the CDC are stark: in the United States, someone has a heart attack every 40 seconds. Every year, about ...

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

A risk score derived from cardiovascular reactivity to mental stress improves prediction of adverse cardiovascular outc ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...

Interventional Cardiology Devices Market size is expected to be worth around USD 38 Billion by 2032 from USD 19 Billion in 2023, growing at a CAGR of 8.0% Lawrence John Prudour +91 91308 55334 ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) were trading at $55, up $29.28, or 113%, on positive interim data from the phase Ib acute hemodynamic trial of its lead product candidate, TX-45.

The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...